vs
Side-by-side financial comparison of Coeptis Therapeutics Holdings, Inc. (COEP) and SciSparc Ltd. (SPRC). Click either name above to swap in a different company.
Coeptis Therapeutics Holdings, Inc. is the larger business by last-quarter revenue ($862.0K vs $461.0K, roughly 1.9× SciSparc Ltd.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -2041.6%, a 1895.2% gap on every dollar of revenue.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
SciSparc Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in the neurological, psychiatric, and gastrointestinal disorder segments. It operates across global biotech markets, leveraging proprietary cannabinoid-based formulation technologies to advance its pipeline of therapeutic candidates.
COEP vs SPRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $862.0K | $461.0K |
| Net Profit | $-1.3M | $-9.4M |
| Gross Margin | 94.8% | 78.1% |
| Operating Margin | -230.6% | -588.5% |
| Net Margin | -146.5% | -2041.6% |
| Revenue YoY | — | -45.1% |
| Net Profit YoY | 55.1% | -155.8% |
| EPS (diluted) | $0.05 | $17.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $862.0K | — | ||
| Q3 25 | $237.4K | — | ||
| Q2 25 | $200.7K | $461.0K | ||
| Q1 25 | $62.9K | — | ||
| Q4 24 | $0 | $466.0K | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | $840.0K | ||
| Q1 24 | $0 | — |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-2.9M | — | ||
| Q2 25 | $-4.3M | $-9.4M | ||
| Q1 25 | $-3.4M | — | ||
| Q4 24 | $-2.8M | $-3.8M | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-3.0M | $-3.7M | ||
| Q1 24 | $-3.0M | — |
| Q4 25 | 94.8% | — | ||
| Q3 25 | 81.0% | — | ||
| Q2 25 | 77.5% | 78.1% | ||
| Q1 25 | 28.2% | — | ||
| Q4 24 | — | 6.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 56.4% | ||
| Q1 24 | — | — |
| Q4 25 | -230.6% | — | ||
| Q3 25 | -1043.2% | — | ||
| Q2 25 | -2252.9% | -588.5% | ||
| Q1 25 | -6452.6% | — | ||
| Q4 24 | — | -813.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -419.9% | ||
| Q1 24 | — | — |
| Q4 25 | -146.5% | — | ||
| Q3 25 | -1220.8% | — | ||
| Q2 25 | -2159.9% | -2041.6% | ||
| Q1 25 | -5440.9% | — | ||
| Q4 24 | — | -813.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -438.0% | ||
| Q1 24 | — | — |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.58 | — | ||
| Q2 25 | $-1.17 | $17.92 | ||
| Q1 25 | $-1.11 | — | ||
| Q4 24 | $-5.35 | $-8.82 | ||
| Q3 24 | $-0.05 | — | ||
| Q2 24 | $-0.08 | $35.70 | ||
| Q1 24 | $-0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $676.6K | $1.5M |
| Total DebtLower is stronger | $150.0K | — |
| Stockholders' EquityBook value | $13.6M | $-81.0K |
| Total Assets | $16.2M | $5.1M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $676.6K | — | ||
| Q3 25 | $421.7K | — | ||
| Q2 25 | $990.6K | $1.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $252.0K | ||
| Q1 24 | — | — |
| Q4 25 | $150.0K | — | ||
| Q3 25 | $150.0K | — | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.7M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | $13.6M | — | ||
| Q3 25 | $10.4M | — | ||
| Q2 25 | $6.1M | $-81.0K | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $3.4M | $8.9M | ||
| Q3 24 | $4.8M | — | ||
| Q2 24 | $-442.6K | $8.7M | ||
| Q1 24 | $-1.1M | — |
| Q4 25 | $16.2M | — | ||
| Q3 25 | $14.2M | — | ||
| Q2 25 | $12.2M | $5.1M | ||
| Q1 25 | $13.5M | — | ||
| Q4 24 | $8.9M | $10.3M | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $4.2M | $10.5M | ||
| Q1 24 | $3.9M | — |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-1.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $-2.2M | — | ||
| Q2 25 | $-2.4M | $-1.9M | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-6.6M | $-2.9M | ||
| Q3 24 | $-1.9M | — | ||
| Q2 24 | $-1.4M | $-2.2M | ||
| Q1 24 | $-1.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.2M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -261.7% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
